Human iPSC-Derived Natural Killer Cells Engineered with Chimeric Antigen Receptors Enhance Anti-tumor Activity

Cell Stem Cell

Volumn 23, Issue 2, 2018, Pages 181-192.e5

  Li, Ye ^a   Hermanson, David L ^b   Moriarity, Branden S ^c   Kaufman, Dan S ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

chimeric antigen receptors; immunotherapy; iPSCs; natural killer cells; ovarian cancer

Indexed keywords

CHIMERIC ANTIGEN RECEPTOR; GAMMA INTERFERON; INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE SYK; TUMOR NECROSIS FACTOR;

ARTICLE; CANCER IMMUNOTHERAPY; CELL ENGINEERING; CHIMERIC ANTIGEN RECEPTOR T-CELL IMMUNOTHERAPY; CONTROLLED STUDY; EMBRYO; ENZYME PHOSPHORYLATION; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; INDUCED PLURIPOTENT STEM CELL; INSULATOR ELEMENT; NATURAL KILLER CELL; OVARY CANCER; PRIORITY JOURNAL; TUMOR VOLUME; TUMOR XENOGRAFT; ANIMAL; CELL CULTURE; CYTOLOGY; GENETICS; IMMUNOLOGY; K-562 CELL LINE; METABOLISM; MOUSE; NONOBESE DIABETIC MOUSE; OVARY TUMOR; SCID MOUSE;

ANIMALS; CELL ENGINEERING; CELLS, CULTURED; FEMALE; HUMANS; INDUCED PLURIPOTENT STEM CELLS; K562 CELLS; KILLER CELLS, NATURAL; MICE; MICE, INBRED NOD; MICE, SCID; OVARIAN NEOPLASMS; RECEPTORS, CHIMERIC ANTIGEN;

EID: 85048946479     PISSN: 19345909     EISSN: 18759777     Source Type: Journal    
DOI: 10.1016/j.stem.2018.06.002     Document Type: Article

References (75)

1. Ahmed, N., Brawley, V.S., Hegde, M., Robertson, C., Ghazi, A., Gerken, C., Liu, E., Dakhova, O., Ashoori, A., Corder, A., et al. Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma. J. Clin. Oncol. 33 (2015), 1688–1696.
2. Altvater, B., Landmeier, S., Pscherer, S., Temme, J., Schweer, K., Kailayangiri, S., Campana, D., Juergens, H., Pule, M., Rossig, C., 2B4 (CD244) signaling by recombinant antigen-specific chimeric receptors costimulates natural killer cell activation to leukemia and neuroblastoma cells. Clin. Cancer Res. 15 (2009), 4857–4866.
3. Bachanova, V., Miller, J.S., NK cells in therapy of cancer. Crit. Rev. Oncog. 19 (2014), 133–141.
4. Bachanova, V., Cooley, S., Defor, T.E., Verneris, M.R., Zhang, B., McKenna, D.H., Curtsinger, J., Panoskaltsis-Mortari, A., Lewis, D., Hippen, K., et al. Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein. Blood 123 (2014), 3855–3863.
5. Barrett, D.M., Singh, N., Porter, D.L., Grupp, S.A., June, C.H., Chimeric antigen receptor therapy for cancer. Annu. Rev. Med. 65 (2014), 333–347.
6. Beatty, G.L., Haas, A.R., Maus, M.V., Torigian, D.A., Soulen, M.C., Plesa, G., Chew, A., Zhao, Y., Levine, B.L., Albelda, S.M., et al. Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies. Cancer Immunol. Res. 2 (2014), 112–120.
7. Bollino, D., Webb, T.J., Chimeric antigen receptor-engineered natural killer and natural killer T cells for cancer immunotherapy. Transl. Res. 187 (2017), 32–43.
8. Bryceson, Y.T., March, M.E., Ljunggren, H.G., Long, E.O., Activation, coactivation, and costimulation of resting human natural killer cells. Immunol. Rev. 214 (2006), 73–91.
9. Burgess-Beusse, B., Farrell, C., Gaszner, M., Litt, M., Mutskov, V., Recillas-Targa, F., Simpson, M., West, A., Felsenfeld, G., The insulation of genes from external enhancers and silencing chromatin. Proc. Natl. Acad. Sci. USA 99:Suppl 4 (2002), 16433–16437.
10. Caligiuri, M.A., Human natural killer cells. Blood 112 (2008), 461–469.
11. Carlsten, M., Childs, R.W., Genetic Manipulation of NK Cells for Cancer Immunotherapy: Techniques and Clinical Implications. Front. Immunol., 6, 2015, 266.
12. Chang, Y.H., Connolly, J., Shimasaki, N., Mimura, K., Kono, K., Campana, D., A chimeric receptor with NKG2D specificity enhances natural killer cell activation and killing of tumor cells. Cancer Res. 73 (2013), 1777–1786.
13. Cheng, M., Chen, Y., Xiao, W., Sun, R., Tian, Z., NK cell-based immunotherapy for malignant diseases. Cell. Mol. Immunol. 10 (2013), 230–252.
14. Childs, R.W., Carlsten, M., Therapeutic approaches to enhance natural killer cell cytotoxicity against cancer: the force awakens. Nat. Rev. Drug Discov. 14 (2015), 487–498.
15. Chowdhury, P.S., Viner, J.L., Beers, R., Pastan, I., Isolation of a high-affinity stable single-chain Fv specific for mesothelin from DNA-immunized mice by phage display and construction of a recombinant immunotoxin with anti-tumor activity. Proc. Natl. Acad. Sci. USA 95 (1998), 669–674.
16. Denman, C.J., Senyukov, V.V., Somanchi, S.S., Phatarpekar, P.V., Kopp, L.M., Johnson, J.L., Singh, H., Hurton, L., Maiti, S.N., Huls, M.H., et al. Membrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cells. PLoS ONE, 7, 2012, e30264.
17. Dhar, P., Wu, J.D., NKG2D and its ligands in cancer. Curr. Opin. Immunol. 51 (2018), 55–61.
18. + Hematopoietic Stem and Progenitor-derived NK Cells in Older Acute Myeloid Leukemia Patients. Clin. Cancer Res. 23 (2017), 4107–4118.
19. Eagle, R.A., Trowsdale, J., Promiscuity and the single receptor: NKG2D. Nat. Rev. Immunol. 7 (2007), 737–744.
20. Fesnak, A.D., June, C.H., Levine, B.L., Engineered T cells: the promise and challenges of cancer immunotherapy. Nat. Rev. Cancer 16 (2016), 566–581.
21. Figueroa, J.A., Reidy, A., Mirandola, L., Trotter, K., Suvorava, N., Figueroa, A., Konala, V., Aulakh, A., Littlefield, L., Grizzi, F., et al. Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy. Int. Rev. Immunol. 34 (2015), 154–187.
22. Garrity, D., Call, M.E., Feng, J., Wucherpfennig, K.W., The activating NKG2D receptor assembles in the membrane with two signaling dimers into a hexameric structure. Proc. Natl. Acad. Sci. USA 102 (2005), 7641–7646.
23. Geller, M.A., Miller, J.S., Use of allogeneic NK cells for cancer immunotherapy. Immunotherapy 3 (2011), 1445–1459.
24. Geller, M.A., Cooley, S., Judson, P.L., Ghebre, R., Carson, L.F., Argenta, P.A., Jonson, A.L., Panoskaltsis-Mortari, A., Curtsinger, J., McKenna, D., et al. A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer. Cytotherapy 13 (2011), 98–107.
25. Giudice, A., Trounson, A., Genetic modification of human embryonic stem cells for derivation of target cells. Cell Stem Cell 2 (2008), 422–433.
26. Grupp, S.A., Kalos, M., Barrett, D., Aplenc, R., Porter, D.L., Rheingold, S.R., Teachey, D.T., Chew, A., Hauck, B., Wright, J.F., et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N. Engl. J. Med. 368 (2013), 1509–1518.
27. Guillerey, C., Huntington, N.D., Smyth, M.J., Targeting natural killer cells in cancer immunotherapy. Nat. Immunol. 17 (2016), 1025–1036.
28. Handgretinger, R., Lang, P., André M.C., Exploitation of natural killer cells for the treatment of acute leukemia. Blood 127 (2016), 3341–3349.
29. Hassan, R., Ho, M., Mesothelin targeted cancer immunotherapy. Eur. J. Cancer 44 (2008), 46–53.
30. Hermanson, D.L., Kaufman, D.S., Utilizing chimeric antigen receptors to direct natural killer cell activity. Front. Immunol., 6, 2015, 195.
31. Hermanson, D.L., Bendzick, L., Pribyl, L., McCullar, V., Vogel, R.I., Miller, J.S., Geller, M.A., Kaufman, D.S., Induced Pluripotent Stem Cell-Derived Natural Killer Cells for Treatment of Ovarian Cancer. Stem Cells 34 (2016), 93–101.
32. Ho, E.L., Carayannopoulos, L.N., Poursine-Laurent, J., Kinder, J., Plougastel, B., Smith, H.R., Yokoyama, W.M., Costimulation of multiple NK cell activation receptors by NKG2D. J. Immunol. 169 (2002), 3667–3675.
33. Imai, C., Iwamoto, S., Campana, D., Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells. Blood 106 (2005), 376–383.
34. Klingemann, H., Boissel, L., Toneguzzo, F., Natural Killer Cells for Immunotherapy - Advantages of the NK-92 Cell Line over Blood NK Cells. Front. Immunol., 7, 2016, 91.
35. Knorr, D.A., Bock, A., Brentjens, R.J., Kaufman, D.S., Engineered human embryonic stem cell-derived lymphocytes to study in vivo trafficking and immunotherapy. Stem Cells Dev. 22 (2013), 1861–1869.
36. Knorr, D.A., Ni, Z., Hermanson, D., Hexum, M.K., Bendzick, L., Cooper, L.J., Lee, D.A., Kaufman, D.S., Clinical-scale derivation of natural killer cells from human pluripotent stem cells for cancer therapy. Stem Cells Transl. Med. 2 (2013), 274–283.
37. Koehl, U., Kalberer, C., Spanholtz, J., Lee, D.A., Miller, J.S., Cooley, S., Lowdell, M., Uharek, L., Klingemann, H., Curti, A., et al. Advances in clinical NK cell studies: Donor selection, manufacturing and quality control. OncoImmunology, 5, 2015, e1115178.
38. Koneru, M., Purdon, T.J., Spriggs, D., Koneru, S., Brentjens, R.J., IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo. OncoImmunology, 4, 2015, e994446.
39. Kwon, H.J., Choi, G.E., Ryu, S., Kwon, S.J., Kim, S.C., Booth, C., Nichols, K.E., Kim, H.S., Stepwise phosphorylation of p65 promotes NF-κB activation and NK cell responses during target cell recognition. Nat. Commun., 7, 2016, 11686.
40. Lanier, L.L., Up on the tightrope: natural killer cell activation and inhibition. Nat. Immunol. 9 (2008), 495–502.
41. Lanier, L.L., Yu, G., Phillips, J.H., Co-association of CD3 zeta with a receptor (CD16) for IgG Fc on human natural killer cells. Nature 342 (1989), 803–805.
42. Liu, E., Tong, Y., Dotti, G., Shaim, H., Savoldo, B., Mukherjee, M., Orange, J., Wan, X., Lu, X., Reynolds, A., et al. Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity. Leukemia 32 (2018), 520–531.
43. Long, E.O., Negative signaling by inhibitory receptors: the NK cell paradigm. Immunol. Rev. 224 (2008), 70–84.
44. Long, E.O., Kim, H.S., Liu, D., Peterson, M.E., Rajagopalan, S., Controlling natural killer cell responses: integration of signals for activation and inhibition. Annu. Rev. Immunol. 31 (2013), 227–258.
45. Love, P.E., Hayes, S.M., ITAM-mediated signaling by the T-cell antigen receptor. Cold Spring Harb. Perspect. Biol., 2, 2010, a002485.
46. Maude, S.L., Teachey, D.T., Porter, D.L., Grupp, S.A., CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Blood 125 (2015), 4017–4023.
47. Miller, J.S., Soignier, Y., Panoskaltsis-Mortari, A., McNearney, S.A., Yun, G.H., Fautsch, S.K., McKenna, D., Le, C., Defor, T.E., Burns, L.J., et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 105 (2005), 3051–3057.
48. Moriarity, B.S., Rahrmann, E.P., Keng, V.W., Manlove, L.S., Beckmann, D.A., Wolf, N.K., Khurshid, T., Bell, J.B., Largaespada, D.A., Modular assembly of transposon integratable multigene vectors using RecWay assembly. Nucleic Acids Res., 41, 2013, e92.
49. Morvan, M.G., Lanier, L.L., NK cells and cancer: you can teach innate cells new tricks. Nat. Rev. Cancer 16 (2016), 7–19.
50. Nakajima, H., Cella, M., Langen, H., Friedlein, A., Colonna, M., Activating interactions in human NK cell recognition: the role of 2B4-CD48. Eur. J. Immunol. 29 (1999), 1676–1683.
51. Ng, E.S., Davis, R., Stanley, E.G., Elefanty, A.G., A protocol describing the use of a recombinant protein-based, animal product-free medium (APEL) for human embryonic stem cell differentiation as spin embryoid bodies. Nat. Protoc. 3 (2008), 768–776.
52. Ni, Z., Knorr, D.A., Clouser, C.L., Hexum, M.K., Southern, P., Mansky, L.M., Park, I.H., Kaufman, D.S., Human pluripotent stem cells produce natural killer cells that mediate anti-HIV-1 activity by utilizing diverse cellular mechanisms. J. Virol. 85 (2011), 43–50.
53. Ni, Z., Knorr, D.A., Kaufman, D.S., Hematopoietic and nature killer cell development from human pluripotent stem cells. Methods Mol. Biol. 1029 (2013), 33–41.
54. Ni, Z., Knorr, D.A., Bendzick, L., Allred, J., Kaufman, D.S., Expression of chimeric receptor CD4ζ by natural killer cells derived from human pluripotent stem cells improves in vitro activity but does not enhance suppression of HIV infection in vivo. Stem Cells 32 (2014), 1021–1031.
55. Porter, D.L., Levine, B.L., Kalos, M., Bagg, A., June, C.H., Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med. 365 (2011), 725–733.
56. Qasim, W., Zhan, H., Samarasinghe, S., Adams, S., Amrolia, P., Stafford, S., Butler, K., Rivat, C., Wright, G., Somana, K., et al. Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells. Sci. Transl. Med., 9, 2017, eaaj2013.
57. Ramos, C.A., Heslop, H.E., Brenner, M.K., CAR-T Cell Therapy for Lymphoma. Annu. Rev. Med. 67 (2016), 165–183.
58. Romee, R., Rosario, M., Berrien-Elliott, M.M., Wagner, J.A., Jewell, B.A., Schappe, T., Leong, J.W., Abdel-Latif, S., Schneider, S.E., Willey, S., et al. Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia. Sci. Transl. Med., 8, 2016, 357ra123.
59. Rosen, D.B., Araki, M., Hamerman, J.A., Chen, T., Yamamura, T., Lanier, L.L., A Structural basis for the association of DAP12 with mouse, but not human, NKG2D. J. Immunol. 173 (2004), 2470–2478.
60. Sakamoto, N., Ishikawa, T., Kokura, S., Okayama, T., Oka, K., Ideno, M., Sakai, F., Kato, A., Tanabe, M., Enoki, T., et al. Phase I clinical trial of autologous NK cell therapy using novel expansion method in patients with advanced digestive cancer. J. Transl. Med., 13, 2015, 277.
61. Sivori, S., Parolini, S., Falco, M., Marcenaro, E., Biassoni, R., Bottino, C., Moretta, L., Moretta, A., 2B4 functions as a co-receptor in human NK cell activation. Eur. J. Immunol. 30 (2000), 787–793.
62. Smyth, M.J., Cretney, E., Kelly, J.M., Westwood, J.A., Street, S.E., Yagita, H., Takeda, K., van Dommelen, S.L., Degli-Esposti, M.A., Hayakawa, Y., Activation of NK cell cytotoxicity. Mol. Immunol. 42 (2005), 501–510.
63. Song, D.G., Ye, Q., Carpenito, C., Poussin, M., Wang, L.P., Ji, C., Figini, M., June, C.H., Coukos, G., Powell, D.J. Jr., In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB). Cancer Res. 71 (2011), 4617–4627.
64. Song, D.G., Ye, Q., Santoro, S., Fang, C., Best, A., Powell, D.J. Jr., Chimeric NKG2D CAR-expressing T cell-mediated attack of human ovarian cancer is enhanced by histone deacetylase inhibition. Hum. Gene Ther. 24 (2013), 295–305.
65. Teachey, D.T., Lacey, S.F., Shaw, P.A., Melenhorst, J.J., Maude, S.L., Frey, N., Pequignot, E., Gonzalez, V.E., Chen, F., Finklestein, J., et al. Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia. Cancer Discov. 6 (2016), 664–679.
66. Themeli, M., Rivière, I., Sadelain, M., New cell sources for T cell engineering and adoptive immunotherapy. Cell Stem Cell 16 (2015), 357–366.
67. Töpfer, K., Cartellieri, M., Michen, S., Wiedemuth, R., Müller, N., Lindemann, D., Bachmann, M., Füssel, M., Schackert, G., Temme, A., DAP12-based activating chimeric antigen receptor for NK cell tumor immunotherapy. J. Immunol. 194 (2015), 3201–3212.
68. Vivier, E., Nunès, J.A., Vély, F., Natural killer cell signaling pathways. Science 306 (2004), 1517–1519.
69. Wilber, A., Linehan, J.L., Tian, X., Woll, P.S., Morris, J.K., Belur, L.R., McIvor, R.S., Kaufman, D.S., Efficient and stable transgene expression in human embryonic stem cells using transposon-mediated gene transfer. Stem Cells 25 (2007), 2919–2927.
70. Woll, P.S., Grzywacz, B., Tian, X., Marcus, R.K., Knorr, D.A., Verneris, M.R., Kaufman, D.S., Human embryonic stem cells differentiate into a homogeneous population of natural killer cells with potent in vivo antitumor activity. Blood 113 (2009), 6094–6101.
71. Xie, F., Ye, L., Chang, J.C., Beyer, A.I., Wang, J., Muench, M.O., Kan, Y.W., Seamless gene correction of β-thalassemia mutations in patient-specific iPSCs using CRISPR/Cas9 and piggyBac. Genome Res. 24 (2014), 1526–1533.
72. Yahata, K., Maeshima, K., Sone, T., Ando, T., Okabe, M., Imamoto, N., Imamoto, F., cHS4 insulator-mediated alleviation of promoter interference during cell-based expression of tandemly associated transgenes. J. Mol. Biol. 374 (2007), 580–590.
73. Yang, Y., Lim, O., Kim, T.M., Ahn, Y.O., Choi, H., Chung, H., Min, B., Her, J.H., Cho, S.Y., Keam, B., et al. Phase I Study of Random Healthy Donor-Derived Allogeneic Natural Killer Cell Therapy in Patients with Malignant Lymphoma or Advanced Solid Tumors. Cancer Immunol. Res. 4 (2016), 215–224.
74. Zhang, T., Sentman, C.L., Cancer immunotherapy using a bispecific NK receptor fusion protein that engages both T cells and tumor cells. Cancer Res. 71 (2011), 2066–2076.
75. Zhang, C., Oberoi, P., Oelsner, S., Waldmann, A., Lindner, A., Tonn, T., Wels, W.S., Chimeric Antigen Receptor-Engineered NK-92 Cells: An Off-the-Shelf Cellular Therapeutic for Targeted Elimination of Cancer Cells and Induction of Protective Antitumor Immunity. Front. Immunol., 8, 2017, 533.